Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07405554 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Zinc Supplementation With Botulinum Toxin for Overactive Bladder

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from May 2026 to Dec 2026v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2026 to Feb 26, 2026
    • Site details revised
    v3
  3. Primary endpoint revised
    • Secondary endpoints: details revised at 2 of 3 entries
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized, double-blind, placebo-controlled trial evaluates whether oral zinc plus phytase supplementation modifies clinical response to intradetrusor botulinum toxin injection in patients with overactive bladder. Participants will receive either zinc plus phytase supplementation or matching placebo for five days prior to intradetrusor botulinum toxin injection. Participants will be followed for six months after treatment to assess need for repeat botulinum toxin injection, urinary symptoms, and patient-reported outcomes related to overactive bladder.
Trial Details
NCT Number NCT07405554
Lead Sponsor Endeavor Health
Conditions
(from sponsor)		 Overactive Bladder (OAB)
Related terms Urinary Bladder, Overactive
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov